Literature DB >> 3516765

Insulin-dependent inhibition of hepatic glycogenolysis by gastric inhibitory polypeptide (GIP) in perfused rat liver.

H Hartmann, R Ebert, W Creutzfeldt.   

Abstract

The effect of porcine gastric inhibitory polypeptide on hepatic glycogen metabolism was investigated in the isolated in situ perfused rat liver. Glycogenolysis was stimulated by infusion of glucagon into the portal vein (half maximal effective portal vein concentration approximately 30 pmol/l). When glucagon was infused at a final portal vein concentration of 0.5 nmol/l, simultaneous addition of insulin inhibited the glucagon-dependent glycogenolysis in a dose-dependent way (half maximal effective concentration for insulin about 2 nmol/l). Gastric inhibitory polypeptide alone at a concentration of 1 nmol/l reduced glucagon-dependent glycogenolysis only slightly. However, when infused simultaneously at low insulin concentrations (0.1 nmol/l), gastric inhibitory polypeptide suppressed hepatic glucose production dose-dependently up to 70%. The data suggest that gastric inhibitory polypeptide exerts direct metabolic effects on hepatic glycogen metabolism predominantly in a situation where insulin is simultaneously present, e.g. following ingestion of glucose.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3516765     DOI: 10.1007/bf00456120

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  15 in total

Review 1.  Identification and actions of gastric inhibitory polypeptide.

Authors:  J C Brown; J R Dryburgh; S A Ross; J Dupré
Journal:  Recent Prog Horm Res       Date:  1975

Review 2.  The incretin concept today.

Authors:  W Creutzfeldt
Journal:  Diabetologia       Date:  1979-02       Impact factor: 10.122

3.  Measurement of hepatic blood flow in the rat. Trans-hepatic catheterization of the hepatic veins.

Authors:  D Dhumeaux; P Berthelot
Journal:  Biol Gastroenterol (Paris)       Date:  1973 Jan-Feb

4.  Antagonism between the effects of insulin and glucagon on the isolated liver.

Authors:  D J Mackrell; J E Sokal
Journal:  Diabetes       Date:  1969-11       Impact factor: 9.461

5.  The hepatic extraction of gastric inhibitory polypeptide and insulin.

Authors:  J B Hanks; D K Andersen; J E Wise; W S Putnam; W C Meyers; R S Jones
Journal:  Endocrinology       Date:  1984-09       Impact factor: 4.736

Review 6.  Afferent and efferent neural roles in liver function.

Authors:  W W Lautt
Journal:  Prog Neurobiol       Date:  1983       Impact factor: 11.685

7.  Modulation by insulin and glucagon of the activation of glycogenolysis by perivascular nerve stimulation in the perfused rat liver.

Authors:  K Beckh; H Hartmann; K Jungermann
Journal:  FEBS Lett       Date:  1982-09-06       Impact factor: 4.124

8.  Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs.

Authors:  T Wasada; K McCorkle; V Harris; K Kawai; B Howard; R H Unger
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

9.  Inhibition of actions of glucagon in adipocytes by gastric inhibitory polypeptide.

Authors:  J Dupre; N Greenidge; T J McDonald; S A Ross; D Rubinstein
Journal:  Metabolism       Date:  1976-11       Impact factor: 8.694

10.  Gastric inhibitory polypeptide enhanced lipoprotein lipase activity in cultured preadipocytes.

Authors:  R H Eckel; W Y Fujimoto; J D Brunzell
Journal:  Diabetes       Date:  1979-12       Impact factor: 9.461

View more
  6 in total

1.  Increases in intestinal glucose absorption and hepatic glucose uptake elicited by luminal but not vascular glutamine in the jointly perfused small intestine and liver of the rat.

Authors:  A Gardemann; Y Watanabe; V Grosse; S Hesse; K Jungermann
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

Review 2.  Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease.

Authors:  A Zarrinpar; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2012-10-11       Impact factor: 8.171

3.  Detection of glycated gastric inhibitory polypeptide within the intestines of diabetic obese (ob/ob) mice.

Authors:  M H Mooney; Y H Abdel-Wahab; L M Morgan; F P O'Harte; P R Flatt
Journal:  Endocrine       Date:  2001-12       Impact factor: 3.633

4.  Gastric inhibitory polypeptide (GIP) hypersecretion in obesity depends on meal size and is not related to hyperinsulinemia.

Authors:  R Ebert; W Creutzfeldt
Journal:  Acta Diabetol Lat       Date:  1989 Jan-Mar

5.  Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes.

Authors:  Victor A Gault; Peter R Flatt; Clifford J Bailey; Patrick Harriott; Brett Greer; Mark H Mooney; Finbarr P M O'harte
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

6.  Effects of GIP on regional blood flow during normoglycemia and hyperglycemia in anesthetized rats.

Authors:  Xiang Gao; Andreas Lindqvist; Monica Sandberg; Leif Groop; Nils Wierup; Leif Jansson
Journal:  Physiol Rep       Date:  2018-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.